Medicare Part B Step Therapy

Drug Class	Non-Preferred Product(s)	Preferred Product(s)	Effective Date
Antimetabolites	Pemfexy	Pemetrexed	01/01/2027
Autoimmune Infused/Infliximab	Remicade Renflexis	Inflectra Avsola	01/01/2027
Avastin/Biosimilars (Oncology)	Avastin Alymsys Vegzelma	Mvasi Zirabev	01/01/2027
Botulinum Toxin, injectable	Myobloc Botox	Dysport Daxxify Xeomin	01/01/2027
Filgrastim - Colony Stimulating Factors	Granix Neupogen Nypozi Releuko	Zarxio Nivestym	01/01/2027
Complement Inhibitors	Enjaymo	Truxima Ruxience Riabni Rituxan	01/01/2027

Medicare Part B Step Therapy

Drug Class	Non-Preferred Product(s)	Preferred Product(s)	Effective Date
Erythropoiesis - Stimulating Agents	Epogen Mircera Procrit	Retacrit Aranesp	01/01/2027
Gonadotropin Releasing Hormone Agonists (Prostate Cancer)	Zoladex	Eligard (leuprolide acetate) Trelstar	01/01/2027
Immune Globulin	Asceniv, Bivigam, Cutaquig Cuvitru Gammaked,GamaSTAN S/D, Gammagard S/D, Gammaplex, Octagam, Panzyga, HyQvia, Xembify Hizentra	Gamunex-C Gammagard Privigen	01/01/2027
Iron Replacement Products (Injectable)	Feraheme Injectafer Monoferric	Ferrlecit INFeD Venofer	01/01/2027
Mitotic Inhibitors	Abraxane	Paclitaxel Docetaxel	01/01/2027

Medicare Part B Step Therapy

Drug Class	Non-Preferred Product(s)	Preferred Product(s)	Effective Date
Multiple Sclerosis	Lemtrada Ocrevus Tysabri	Avonex, Briumvi, Dimethyl Furamate, Glatiramer, Mayzent	01/01/2027
Osteoporosis- Bone Density	Evenity	Bildyos Enoby	01/01/2027
Rheumatoid Arthritis	Actemra Orencia Remicade Simponi Aria	Tyenne Inflectra Renflexis Avsola	01/01/2027
Rituximab (Oncology and Rheumatology)	Rituxan Rituxan Hycela	Truxima Ruxience Riabni	01/01/2027

Medicare Part B Step Therapy

Drug Class	Non-Preferred Product(s)	Preferred Product(s)	Effective Date
Trastuzumab (Oncology)	Herceptin Herceptin Hylecta Herzuma Ogivri Ontruzant Hercessi	Kanjinti Trazimera	01/01/2027
Treanda (Oncology)	Treanda	Bendamustine Bendeka Belrapzo	01/01/2027
Ulcerative Colitis	Entyvio Remicade Stelara	Inflectra Renflexis Avsola	01/01/2027
Ophthalmology – Vascular Endothelial Growth Factor Inhibitors Products (VEGF inhibitors)	Lucentis	Avastin Byooviz Cimerli Vabysmo	01/01/2027
Tocilizumab Products	Actemra	Tyenne Tofidence	01/01/2027

Medicare Part B Step Therapy

Drug Class	Non-Preferred Product(s)	Preferred Product(s)	Effective Date
Ustekinumab Products	Stelara Imuldosa Steqeyma Wezlana Pyzchiva	Selarsdi Yesintek Ustekinumab-aauz	01/01/2027
Tremfya	Tremfya	Selarsdi Yesintek Ustekinumab-aauz	01/01/2027
Eculizumab Products	Soliris	Bkemv Epysqli	01/01/2027
Denosumab Products	Xgeva	Bilprevda	01/01/2027
Infliximab Products	Infliximab (authorized generic) Remicade	Avsola Inflectra Renflexis	01/01/2027

Medicare Part B Step Therapy

Drug Class	Non-Preferred Product(s)	Preferred Product(s)	Effective Date
Migraine Products	Vyepti	Emgality	01/01/2027
Viscosupplemens	Durolane, Euflexxa, Gel-One, Gelsyn-3, GenVisc 850, Hymovis-One, Monovisc, Orthovisc, Supartz FX, SynoJoynt, Synvisc, Synvisc-One, TriVisc, Visco-3	Hyalgan Hymovis Triluron	01/01/2027
Pegfilgrastim Products- GM-CSF Granulocyte-macrophage colony-stimulating factor	Ziextenzo, Nyvepria, Fylnetra, Stimufend, Armlupeg, Neulasta, Neulasta Onpro , Udenyca, Udenyca Onbody	Fulphila	01/01/2027